ArticleFrontiers in neurology
Comparative characteristics of homocysteine and uric acid in patients with Parkinson's disease-related cognitive impairment and post-stroke cognitive impairment.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare homocysteine (Hcy) and uric acid (UA) levels between patients with Parkinson's disease with cognitive impairment (PD-CI) and those with post-stroke cognitive impairment (PS-CI), and to analyze the correlation of these biomarkers with cognitive function and their heterogeneity across different disease types. Methods: Patients diagnosed with cognitive impairment who were admitted to the Department of Neurology at Yangjiang Hospital of Traditional Chinese Medicine between January 2025 and December 2025 were included (60 PD-CI; 60 PS-CI). Blood Hcy and UA levels were uniformly measured, and cognitive function was assessed using the Mini-Mental State Examination (MMSE). Covariance analysis compared biomarker level differences between groups. Spearman correlation analysis and multivariate linear regression models with interaction terms explored the relationship between biomarkers and MMSE scores. Binary logistic regression identified factors independently associated with disease type. Results: After adjusting for confounding factors, the PD-CI group exhibited significantly higher Hcy levels (adjusted mean difference: 2.55 μmol/L, 95% CI: 0.23-4.87, Conclusion: Patients with PD-CI and PS-CI exhibit distinct metabolic profiles, with the PD-CI group characterized by elevated Hcy and low UA levels. Although elevated Hcy is a common factor associated with cognitive impairment in both conditions, UA levels in this cohort were independently associated with PD-CI (relative to PS-CI), not with MMSE scores. These findings suggest potential differences in metabolic profiles and may offer new insights for clinical differential diagnosis. As an exploratory cross-sectional analysis, these findings require validation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.